GLP-1 and weight loss stocks

Extremely high; GLP-1 products comprise approximately 75% of total revenue.

Novo Nordisk is a leading GLP-1 drug developer that consumes commercial-scale peptide API.

Novo Nordisk relies on the manufacturing and supply of complex injection pens for Wegovy and Ozempic.

Novo Nordisk is a leading GLP-1 drug developer whose products require commercial-scale peptide API supply.

Dominates market with incretins (GIP/GLP-1) and developing triple agonists.

Lilly is a primary branded GLP-1 manufacturer and a major consumer of peptide API capacity.

Eli Lilly is a downstream branded GLP-1 developer and peptide-API consumer, not a CDMO competitor.

Lupin has both semaglutide injectable products and expanding in-house peptide manufacturing capacity.

Lupin is identified as an injectable semaglutide manufacturer with expanding peptide capacity.

Lupin combines semaglutide injectable products with in-house peptide manufacturing expansion.

Lupin is identified as an Indian manufacturer making semaglutide injectable products and is expanding in-house peptide manufacturing. A successful U.S. litigation pathway for generic semaglutide would validate the commercial opportunity and increase the value of Lupin’s peptide and generic manufacturing capabilities.

Bachem is a specialized peptide manufacturer with direct sensitivity to commercial-scale GLP-1 API demand and utilization.

Successful durable obesity therapies can expand commercial-scale peptide API and CDMO demand that Bachem may capture.

A successful large-scale peptide obesity program can increase demand for peptide API development and commercial manufacturing. Bachem is a specialized peptide CDMO, but the available evidence does not identify a product-specific Zealand or Roche supply agreement.

Persistent GLP-1 demand can create incremental commercial-scale peptide API and CDMO work for Bachem. The impact is positive but indirect because the retrieved evidence establishes Bachem's peptide-manufacturing position rather than a specific GLP-1 customer contract.

Stevanato’s cartridges and prefilled-syringe platforms scale directly with production and dispensing of injectable GLP-1 medicines.

Stevanato Group's Alina pen platform and Nexa cartridges directly leverage injectable GLP-1 sales, which reached DKK 19.48 billion for Wegovy in Q2.

Stevanato Group provides specialized drug containment and delivery platforms, such as the Alina pen injector, which are widely used for GLP-1 and other peptide therapies. Surging volumes and raised revenue guidance from Lilly directly translate to increased sales momentum for Stevanato's proprietary devices.

Ypsomed's stated specialization in pen-injection devices and prefilled-cartridge manufacturing directly matches the approved delivery formats, although sourcing is unconfirmed.

Lonza has peptide API and injectable fill-finish capabilities relevant to outsourced GLP-1 production.

Lonza can capture peptide API and injectable fill-finish revenue if additional GLP-1 programs move through development and scale-up.

Lonza has peptide API synthesis and injectable fill-finish capabilities that can capture outsourced metabolic-drug volume as commercial programs scale.

Expanded demand for injectable incretins should support outsourced peptide synthesis and commercial manufacturing. The retrieved context specifically identifies Lilly's partnership with Lonza for peptide synthesis, providing a more concrete supply-chain pathway than generic CDMO exposure.

West supplies injectable delivery components and is expanding capacity for GLP-1-related injectable volumes.

West Pharmaceutical Services manufactures critical components and delivery systems for GLP-1 injectables.

West is an injectable-packaging component supplier, not a drug owner or peptide API manufacturer.

Branded injectable GLP-1 volume creates incremental demand for West's delivery components and manufacturing capacity.

As a key supplier of injectable delivery systems, WST benefits from the expansion of high-volume metabolic pipelines. The success of next-gen injectables like retatrutide ensures long-term demand for specialized containment and delivery components.

Hybio has stated GLP-1 peptide API capabilities and an integrated peptide manufacturing chain.

Hybio has large-scale peptide synthesis capacity and stated GLP-1 API output. Expansion of China’s GLP-1 market and the approaching generic wave can create incremental API demand, although the company is exposed to competitive pricing among peptide suppliers.

Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.

Glenmark is identified as making semaglutide injectable pens, creating direct finished-product exposure.

Sun Pharma’s synthetic semaglutide pen gives it positive exposure to increased injectable generic volume as more patients gain access to lower-cost products.

Telehealth prescribing and medication management complement the shift from traditional obesity care toward chronic pharmacotherapy, potentially increasing patient acquisition and recurring service demand.

Growing platform volume driven by demand for oral obesity treatments.

Hims & Hers is the direct beneficiary of the new information: Q2 revenue grew 38%, subscribers reached nearly 2.9 million, and full-year revenue guidance increased to $3.1–$3.3 billion. However, the branded GLP-1 transition is dilutive to near-term profitability, with adjusted gross margin falling to 64% from 76% and free cash flow negative.

Very high; $14B in GLP-1 revenue per quarter makes it a massive component of their pharmaceutical segment growth.

McKesson is an enabling distributor for the shift toward recurring prescription-based obesity treatment, though it is not a direct clinical beneficiary of the medical savings.

Higher branded GLP-1 prescription and shipment volumes can modestly increase McKesson's pharmaceutical-wholesale revenue and handling volume as obesity care shifts toward recurring medicines. The effect is limited because direct-to-consumer, specialty, and manufacturer-affiliated fulfillment can bypass portions of the traditional wholesaler channel.

Cited slower GLP-1 growth as a primary reason for lowering their consolidated revenue outlook.

Rapid growth in injectable GLP-1 prescriptions can increase refrigerated pharmaceutical warehousing, distribution, and specialty-fulfillment volumes for Cencora. The positive impact is conditional because the development does not disclose a Cencora mandate or identify the medicines supplied through MedPal.

PolyPeptide can capture incremental peptide API volume as obesity and diabetes injectable programs move from development toward commercial supply.

PolyPeptide can capture incremental peptide API and CDMO volume as obesity programs move from clinical development toward commercial supply.

PolyPeptide is identified as part of the constrained peptide-CDMO buildout supporting GLP-1 therapies.

Slightly positive but indirect: Validation of a higher-efficacy incretin category can support further commercial peptide synthesis and API-capacity demand across diabetes and obesity programs. No direct Lilly or Novo contract is evidenced.

The Phase 3 transition increases the potential future pool of outsourced peptide synthesis and commercial API work. PolyPeptide is an upstream capacity beneficiary rather than a competing obesity-drug owner, and no product-specific contract is disclosed.

PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.

Thermo Fisher is converting facilities to fill pens for obesity and diabetes medicines, placing it in the injectable manufacturing and fill-finish chain.

Thermo Fisher’s relevant role is outsourced sterile manufacturing and fill-finish for injectable obesity and diabetes medicines.

Thermo Fisher is identified among CDMO beneficiaries of GLP-1 fill-finish and peptide manufacturing expansion.

Rapid growth in injectable incretin demand can increase outsourced sterile manufacturing, fill-finish, testing, analytical, and packaging work. Thermo Fisher is an indirect capacity beneficiary rather than an owner of a competing obesity drug, and no product-specific award is disclosed.

Higher commercial incretin volumes can increase demand for outsourced sterile manufacturing, device assembly, analytical, and packaging services. Thermo Fisher is expanding capacity for prefilled syringes, vials, cartridges, and autoinjectors, although no Lilly-specific award is disclosed.

CSPC is nearing generic semaglutide commercialization, creating direct API and finished-product volume capture potential.

Novo’s milestone increases the visibility and addressable size of China’s GLP-1 market while reinforcing the opportunity for CSPC’s lower-cost semaglutide follow-on products as patent and regulatory pathways open to domestic entrants.

Commercial oral GLP-1 adoption directly supports demand for Pharmaron's oral solid-dose development and contract-manufacturing services.

Pharmaron is identified as a contract manufacturer supporting oral solid-dose GLP-1 production.

Commercialization of oral GLP-1 products increases potential demand for localized formulation, oral solid-dose development, and manufacturing services. Pharmaron may capture service revenue as additional programs scale, but no specific Wegovy contract is disclosed.

Oral GLP-1 commercialization increases the need for localized formulation and manufacturing capacity. Pharmaron is identified as a Chinese CDMO partner supporting oral GLP-1 supply-chain expansion, creating potential service revenue as programs move toward commercial scale.

Increased volume of prefilled GLP-1 syringes and cartridges drives demand for Aptar's plungers and needle shields.

Aptar Pharma supplies packaging and components used in GLP-1 drug-delivery systems.

AptarGroup provides specialized closure solutions, prefilled syringe plungers, and cartridge plungers optimized for GLP-1 applications. Eli Lilly's expansion of U.S. manufacturing capacity for metabolic and injectable treatments represents a direct commercial driver for Aptar's high-growth injectables division.

Aptar Pharma provides key containment and delivery solutions, such as prefilled syringe plungers and cartridge plungers, explicitly designed for GLP-1 receptor agonist applications. The upward revision of Lilly's guidance is highly positive, signaling a sustained expansion of the market for injectable weight-loss and diabetes treatments.

Developing pemvidutide, which is also a 1:1 GLP-1/glucagon dual agonist.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Structure is developing an oral small-molecule GLP-1 receptor agonist, creating direct pipeline exposure to the oral obesity segment.

Structure has an obesity program but is not evidenced as a current commercial incretin manufacturer or supply-chain provider.

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Pfizer has oral GLP-1 pipeline exposure, but its EU revenue opportunity is prospective rather than tied to a currently marketed product.

Increased scarcity value of high-efficacy obesity assets with good safety.

Advancing VK2735 into Phase III materially increases Viking’s probability of eventual commercialization, strategic partnering, and revenue from a dual GLP-1/GIP obesity therapy. The program covers both injectable and oral formulations, while maintenance-dosing research could differentiate the product through less frequent administration.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.

Medtide Inc. operates as a contract research, development, and manufacturing organization (CRDMO), providing comprehensive services across the entire pharmaceutical lifecycle, from initial drug discovery and preclinical investigation through to clinical development and commercial-scale production. The company specializes in the synthesis of novel peptide chemical entities for discovery purposes, along with the development of peptide-based chemistry, manufacturing, and control (CMC) processes, and their subsequent commercial manufacturing. A core area of its developmental focus is on glucagon-like peptide-1 (GLP-1) molecules, which it designs for both oral and/or injectable administration. Medtide leverages a suite of proprietary research and development platforms, including OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. Its client base spans multiple regions globally, including China, the United States, Japan, Europe, South Korea, and Australia. Established in 2020 as Taide Pharmaceutical (Zhejiang) Co., Ltd, the company rebranded to Medtide Inc. in February 2023 and maintains its headquarters in Hangzhou, China.

Medpace offers integrated obesity-trial execution, central laboratory, bioanalytical, and site-selection capabilities and could capture outsourced study revenue.

Progression of an obesity candidate into multiple-ascending-dose testing can support incremental demand for outsourced trial execution, recruitment, central laboratory, and bioanalytical services. No specific Structure contract is disclosed, so the potential benefit is indirect.

Omada has meaningful employer and PBM distribution exposure through GLP-1 care and national-plan integrations, but it is a care-management platform rather than a full PBM.

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

IQVIA’s evidenced exposure is CRO execution and clinical-data work for obesity trials rather than ownership of an obesity therapy.

Asymchem has identified peptide synthesis capacity that can support GLP-1 programs.

A China oral Wegovy milestone supports broader GLP-1 development and manufacturing demand. Asymchem has expanding peptide solid-phase synthesis capacity, so additional programs from branded, domestic, and generic developers could increase peptide API and CDMO revenue.

Asymchem has peptide synthesis capacity that can support branded, domestic, and generic GLP-1 programs. A larger China MASH market can increase peptide API and contract-development demand, although no product-specific Novo contract is identified.

WuXi has an outsourced peptide-synthesis segment exposed to the broader GLP-1 manufacturing cycle.

WuXi Biologics is discussing prefilled-syringe capacity, directly linking it to the injectable fill-finish portion of the obesity-drug chain.

OneSource benefits from increased demand for its licensed tirzepatide dossier and associated licensing economics, although payment terms are undisclosed.

OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.

GLP-1s accounted for 5% of their total 16% revenue growth, indicating significant but slightly lower dependency than peers.

Amazon’s Pharmacy and One Medical businesses participate in the integrated digital prescribing and fulfillment stack, creating positive exposure to expanding online GLP-1 access.

Hikma has a semaglutide dossier, but the retrieved evidence does not establish its peptide API, fill-finish, or device manufacturing role.

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

Teladoc is a broad telehealth company with exposure to digital obesity management, but its overlap is less concentrated in GLP-1 weight management than the target's.

Teladoc is a listed telehealth competitor, and the proposed acquisition could increase competitive intensity in nationwide virtual care and weight-management services. The effect is limited because the target appears focused on a narrower GLP-1, hormone-health, longevity, and sexual-wellness platform rather than Teladoc's entire service portfolio.

Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.

CVS can capture pharmacy dispensing, Caremark formulary, rebate, and prescription-management activity as obesity treatment shifts toward recurring medicines.

Greater use of chronic obesity medicines can increase CVS pharmacy dispensing, PBM formulary management, claims administration, and rebate-negotiation activity. The net benefit is limited by higher drug spending and potential payer pressure over rebates and utilization management.

Express Scripts can benefit from rebate negotiation and clinical-management activity as evidence improves the case for managed obesity-drug coverage.

The new cost evidence can support broader obesity-drug management and utilization through Cigna's Evernorth and Express Scripts businesses. More competition and evidence-based formulary decisions can improve rebate negotiation and clinical-management revenue, although higher drug utilization also increases plan spending for covered members.